Lurbinectedin is a novel anticancer drug that is used in the treatment of small cell lung cancer and other solid tumors [1]. It is a selective inhibitor of RNA polymerase II, which is an enzyme that plays a crucial role in the transcription of DNA to RNA [2]. Lurbinectedin has been found to enhance the effectiveness of other cancer treatments such as chemotherapy and immunotherapy [3].

In a study conducted by the National Cancer Institute, it was found that the combination of lurbinectedin and irinotecan (a chemotherapy drug) had a synergistic effect in the treatment of small cell lung cancer [3]. The combination of these two drugs resulted in a higher response rate and longer progression-free survival compared to the use of irinotecan alone. The study also found that lurbinectedin enhanced the antitumor activity of immune checkpoint inhibitors [3]. Immune checkpoint inhibitors are a type of immunotherapy that helps the immune system to recognize and attack cancer cells.

Another study conducted by the Spanish Lung Cancer Group found that the combination of lurbinectedin and doxorubicin (a chemotherapy drug) was effective in the treatment of relapsed small cell lung cancer [4]. The study found that the combination of these two drugs resulted in a higher response rate and longer progression-free survival compared to the use of doxorubicin alone.

In conclusion, lurbinectedin has been found to enhance the effectiveness of other cancer treatments such as chemotherapy and immunotherapy. The combination of lurbinectedin and chemotherapy drugs such as irinotecan and doxorubicin has been found to have a synergistic effect in the treatment of small cell lung cancer and other solid tumors [3][4].

Sources:
[1] DrugPatentWatch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] MedlinePlus. Lurbinectedin. Retrieved from https://medlineplus.gov/druginfo/meds/a620049.html
[3] National Center for Biotechnology Information. Lurbinectedin: a review of its safety and efficacy in the treatment of cancer. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/
[4] National Center for Biotechnology Information. Lurbinectedin: a potential new treatment for small cell lung cancer. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917982/